GRACEcast - Discussions with the Global Resource for Advancing Cancer Education: Recent Episodes
cancerGRACE
In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership.
We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis.
For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums
Dr. Steven Bialick discusses the various symptoms that may be present with pancreatic cancer.
Dr. Steven Bialick discusses the types of lab tests done on patients with suspected pancreatic cancer, including CBC, CMP, CEA, and CA19-9.
Dr. Steven Bialick discusses the NCCN guidelines for diagnosing pancreatic cancer, as well as the various members of a patient's care team.
Dr. Steven Bialick discusses genetic testing in pancreatic cancer, including the difference in germline and somatic testing, and which mutations may have known treatments.
Dr. Steven Bialick discusses the main risk factors for pancreatic, including high BMI, smoking, and alcohol abuse.
Dr. Steven Bialick discusses how pancreatic cancer rates are increasing, and overall patterns of diagnosis.
Dr. Steven Bialick discusses the anatomy of pancreas cancer, including why a person may experience weight loss.
Dr. Steven Bialick discusses how location and stage affect prognosis in pancreatic cancer.
Dr. Steven Bialick discusses the types of imaging tests used in diagnosing pancreatic cancer, including CT and PET scans.
Dr. Vernon Sondak discusses alternatives for non-surgical candidates with skin cancer, including systemic therapy.
Dr. Fiorinda Muhaj discusses the risk factors for developing BCC, and how it is diagnosed.
Dr. Vernon Sondak discusses the recent developments in systemic therapy to treat patients with skin cancer.
Dr. Vernon Sondak discusses potential downsides to Mohs surgery, and why not all patients will go that route.
Dr. Vernon Sondak gives a brief overview of melanoma, and what warning signs to look for. He also gives important information regarding skin cancer prevention overall.
Dr. Fiorinda Muhaj discusses how patients with BCC can follow up after treatment, and how to help prevent future BCC occurrences.
Dr. Vernon Sondak explains what Mohs surgery is, and why it may be preferable in some cases.
Dr. Vernon Sondak discusses two common types of skin cancer: basal and squamous cell. He details their characteristics and statistics.
Dr. Vernon Sondak explains the basics of skin cancer facts: how prominent it is, who is at risk, and what it can look like.
Drs. Desai and Abu Rous discuss trial data from Flaura2 and Mariposa as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.
Drs. Desai and Abu Rous discuss the Crown study data as presented at ASCO 2024, and its implications in treating ALK+ NSCLC.
Drs. Desai and Abu Rous discuss the data, as presented at ASCO 2024, and how it may change the field of treatment for limited stage small Adriatic Studycell lung cancer.
Drs. Desai and Abu Rous discuss trial date from Mariposa2 and Laura as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.
Drs. Desai and Abu Rous discuss using tarlatamab in treating extensive stage small cell lung cancer.
Drs. Patel, Sheth, and Weiss discuss emerging data and advances in thyroid cancer treatment.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in incurable HPV negative head and neck cancer.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in recurrent/metastatic HPV positive head and neck cancer.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in curable HPV negative head and neck cancer.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in curable HPV positive head and neck cancer.
Dr. Marco Ruiz explains the concept of bone marrow transplant, and how it is used in treating blood cancers.
Drs. Goodman, Phillips, Taneja, and Rajeeve discuss whether a patient's location can affect the treatments they can access and their overall prognosis.
Drs. Goodman, Phillips, Taneja, and Rajeeve discuss how to navigate treatment and Covid vaccination.
Dr. Sridevi Rajeeve discusses current FDA approved bispecific antibodies and ones coming from clinical trials.
Dr. Alankrita Taneja examines data from the CESAR trial, and discusses curative strategies for Smoldering Multiple Myeloma.
Dr. Sridevi Rajeeve discusses possible side effects from bispecific antibodies, and how to manage them.
Dr. Sridevi Rajeeve discusses the unprecedented response rates in patients treated with teclistamab, talquetamab, and elranatamab, as well as their clinical trial data.
Dr. Tycel Phillips examines the efficacy of two medications against diffuse large b-cell lymphoma (DLBCL)
Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.
Dr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC
Dr. Joshua Reuss discusses the ADAURA trial, which suggested Osimertinib as treatment for EGFR+ NSCLC.
Dr. Aakash Desai discusses the administration of therapy for biomarkers, and how to overcome the gaps in administration, access, and affordability.
Dr. Aakash Desai discusses the current recommendations for biomarker testing in patients with NSCLC, as well as best practices.
Dr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.
Dr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.
Dr. Joshua Reuss examines important details learned during the ADAURA trial, including overall survival, reduced risk of brain mets, and side effects.
Dr. Aakash Desai gives a basic overview of biomarkers, and discusses which ones are important for patients with NSCLC.
Dr. Aakash Desai details the importance of biomarker testing, and discusses the method of liquid biopsy to do so.
Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.
Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC.
Dr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT).
Dr. Joshua Reuss explains why immunotherapy is not typically given to patients with resectable NSCLC and a driver mutation.
Dr. Joshua Reuss discusses treatment options for patients with locally advanced NSCLC, and how to proceed while waiting for trial data.
Dr. Puneeth Iyengar discusses local therapy options for patients with metastatic disease who have received a front line therapy.
Dr. Joshua Reuss discusses what the patient can do to advocate for themselves during treatment.
Dr. Joshua Reuss discusses considerations and questions for targeted therapy before surgery.
Dr. Puneeth Iyengar discusses local therapy treatment options for patients who have oligoprogressive disease.
Dr. Puneeth Iyengar examines what has been learned from studies, what still remains unanswered, and future directions of local therapy treatments for patients with NSCLC.
Dr. Puneeth Iyengar looks at current statistics for methods of adding to targeted therapy, as well as giving an overview of biology in treatment.
डॉ. अलंकृता तनेजा ट्रांसजेंडर मरीजों में देखे जाने वाले सामान्य परामर्श मुद्दों पर चर्चा करती हैं, और सही मॉनिटरिंग का महत्व बताती हैं।
(Dr. Alankrita Taneja discusses common consultation issues seen in transgender patients, and the importance of proper monitoring.)
डॉ. अलंकृता तनेजा टेस्टोस्टेरोन थेरेपी और इसके साथ आने वाले जोखिमों पर चर्चा करती हैं, जिसमें द्वितीय एरिथ्रोसाइटोसिस भी शामिल है।
(Dr. Alankrita Taneja discusses testosterone therapy and the risks that come with it, including secondary erythrocytosis.)
डॉ. अलंकृता तनेजा सिकल सेल रोग वाले लोगों के लिए उपचार विकल्पों की जांच करती हैं, जो जेंडर अफर्मिंग हार्मोन थेरेपी के अधीन हैं।
(Dr. Alankrita Taneja examines the treatment options for people with Sickle Cell Disease who are undergoing gender affirming hormone therapy.)
डॉ. अलंकृता तनेजा एस्ट्रोजन थेरेपी और इसके संभावित दुष्प्रभावों की जांच करती हैं।
(Dr. Alankrita Taneja examines estrogen therapy and its potential side effects.)
डॉ. अलंकृता तनेजा भारत में ट्रांसजेंडर लोगों के संबंधित शब्दावली और सामाजिक मुद्दों का एक संक्षिप्त विवरण देती है।
(Dr. Alankrita Taneja gives a brief description of terminology and social issues surrounding transgender people in India.)
Dr. Vernon Sondak makes the argument that neoadjuvant therapy leads to a better immune response in patients with melanoma.
Dr. Vernon Sondak discusses the pros and cons of neoadjuvant therapy, or receiving treatment before surgery.
Dr. Vernon Sondak discusses the pros and cons of adjuvant therapy, or receiving treatment after surgery.
Dr. Meredith McKean discusses recent findings in adjuvant therapy for patients with stage 3 or 4 melanoma.
Dr. Vernon Sondak discusses current patient treatment standards, including using immune therapy before targeted therapy in unresectable stage 4 disease.
Dr. Vernon Sondak examines the PRADO trial and what it means for drug regimens moving forward.
Dr. Michael Postow looks at potential side effects for patients with melanoma who receive immunotherapy.
Dr. Vernon Sondak looks at the recent improvements in treatment of metastatic melanoma, including the Relativity 047 trial.
Dr. Michael Postow gives a brief explanation of what melanoma is and how it forms, and discusses current treatment options.
Dr. Aaron Goodman gives a brief explanation of three current types of CAR-T cell therapy.
Dr. Aaron Goodman discusses two main side effects of CAR-T Cell Therapy: Cytokine Release Syndrome and ICANS.
Dr. Aaron Goodman discusses treatment options for patients who relapse after R-CHOP first line treatment.
Dr. Joshua Brody discusses the use of bispecific antibodies in the treatment of Non-Hodgkin's Lymphoma.
Dr. Joshua Brody gives an in-depth explanation of CAR-T cells and their role in treating Non-Hodgkin's Lymphoma.
Dr. Devika Das gives a brief overview of the importance of lung cancer screening during a pandemic.
Dr. Devika Das examines the first domain of quality cancer care: finding the cancer early.
Dr. Devika Das discusses the importance of staging of cancer, and of testing for mutations.
Dr. Devika Das discusses the genetic component of lung cancer mutations, and if they can be passed on.
Dr. Medhavi Gupta discusses how common breast cancer is, and why it is crucial to get screened.
Dr. Medhavi Gupta discusses mammograms, ultrasounds, and MRIs for breast cancer screening.
Dr. Medhavi Gupta examines the steps a patient could go through after an abnormality is found on a breast cancer screening.
Dr. Devika Das examines the importance of patient centered care, including safety throughout the process, and equitable care for all.
Dr. Devika Das discusses comprehensive care in lung cancer, and who is involved from screening to treatment.
Dr. Medhavi Gupta examines how treatment can look for patients diagnosed with breast cancer.
Dr. Medhavi Gupta reiterates the importance of breast cancer screening in detection and treatment.
Dr. Chul Kim explains EGFR mutations and their prevalence, particularly in Asian and Caucasian communities.
Dr. Chul Kim takes a look at the FLAURA Trial on untreated advanced NSCLC, and the role Osimertinib played in the trial.
Dr. Tejas Patil discusses when to utilize molecular testing in patients with NSCLC. For full video visit cancerGRACE.org.
Dr. Melina Marmarelis discusses the use of chemotherapy with and without immunotherapy in patients with mesothelioma.
Dr. Melina Marmarelis discusses the various surgical options for patients with mesothelioma.
Dr. Melina Marmarelis discusses how doctors diagnose mesothelioma and determine the stage of the disease.
Doctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss their opinions on costs and treatment options, such as double dose Osimertinib
Doctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss the role telemedicine can play in cancer treatment.
Doctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss the effectiveness of liquid biopsies at detecting TKI resistance for fusions such as ALK, ROS1, and RET.
Doctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss whether there is a case for testing both pleural fluid and blood biopsy.
Doctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss the coverage, cost, and standard of care for liquid and tissue biopsy monitoring.
Doctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss whether circulating tumor DNA testing will replace marker testing.
Doctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss which tests are relevant for which diagnoses in lung cancer.
Doctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss the usage of liquid and tissue biopsies in patients with acquired resistance.
Doctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss anxiety and symptom burden, and balancing the wait for biopsy results vs. starting treatment.
Doctors Jared Weiss, Ibiayi Dagogo-Jack, and Jeffrey Thompson discuss the challenges and uses of liquid and tissue biopsies in patients with acquired resistance.
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Meredith McKean discusses the importance of skin cancer screenings.
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
Dr. Roman Groisberg discusses Leptomeningeal disease and brain metastases in melanoma patients.
A huge thank you to our sponsors #Merck and #Exelixis!
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Meredith McKean discusses neoadjuvant treatment for melanoma patients.
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
Dr. Meredith McKean discusses molecular profiling and driver mutations in patients with melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Douglas Johnson discusses treatment options for patients with metastatic melanoma.
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Douglas Johnson discusses the potential toxicities that are associated with immunotherapy in melanoma patients.
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Brain Metastases in Breast Cancer, Risks of Developing Brain Metastasis in Breast Cancer with Dr. Medhavi Gupta and Dr. Jessica Young
Brain Metastases in Breast Cancer, Treatment Options and Efficacy with Dr. Medhavi Gupta and Dr. Nancy Lin
Dr. Jack West, Dr. Benjamin Levy, and Dr. Jared Weiss discuss the recent trends and lessons learned from Covid-19 in telemedicine for cancer patients.
Dr. Jack West, Dr. Benjamin Levy, and Dr. Jared Weiss discuss the benefits and drawbacks of telemedicine for cancer patients.
Dr. Jack West, Dr. Benjamin Levy, and Dr. Jared Weiss discuss the safety of masking in opened businesses during the pandemic, especially for cancer patients.
Dr. Jack West, Dr. Benjamin Levy, and Dr. Jared Weiss discuss the role of oncologists and the importance of patient education during the ongoing Covid-19 pandemic.
Dr. Jack West, Dr. Benjamin Levy, and Dr. Jared Weiss discuss the Covid vaccine in relation to cancer patients.
Brain Metastases in Breast Cancer
Treatment Options for Breast Cancer Patients who Relapse with Only CNS Metastases
Dr. Medhavi Gupta
Dr. Nancy Lin
Brain Metastases in Breast Cancer -
Patients with Brain Metastases in Breast Cancer - Prognosis and Impact on Survival with Dr. Medhavi Gupta and Dr. Nancy Lin
Meredith McKean MD, MPH with Sarah Cannon Research Institute, Douglas Johnson, MD, Assistant Professor of Medicine at Vanderbilt, and Roman Groisberg, MD Medical Oncologist at Rutgers Health joined GRACE to discuss current updates in treatment for Melanoma.
Dr. Roman Groisberg discusses options for adjuvant treatment in patients with melanoma.
A huge thank you to our sponsors #Merck and #Exelixis!
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Metastatic Triple Negative Breast Cancer, Immunotherapy Treatment Options and Potential Side Effects with Dr. Medhavi Gupta and Dr. Aditya Bardai
In this episode, Dr. Jared Weiss and Dr. Siddharth Sheth discuss palliative care for incurable head and neck cancers, and recent studies regarding the subject.
In this episode, Dr. Jared Weiss and Dr. Siddharth Sheth discuss the role HPV plays in head and neck cancers.
In this episode, Dr. Jared Weiss and Dr. Siddharth Sheth discuss recent developments in curative modalities as well as immunotherapy in head and neck cancers.
Metastatic Triple-Negative Breast Cancer Antibody-Drug Conjugate Treatment Options with Dr. Medhavi Gupta and Dr. Aditya Bardai
Metastatic Triple Negative Breast Cancer Targeted Therapy Treatment Options and Potential Side Effects with Dr. Medhavi Gupta and Dr. Aditya Bardai
Surgical Management in Breast Cancer, Body Image and Reconstruction Surgery with Dr. Medhavi Gupta and Dr. Jessica Young
Surgical Management in Breast Cancer, What to Expect During Surgery with Dr. Medhavi Gupta and Dr. Jessica Young
Surgical Management in Breast Cancer, Long Term Outcomes - Breast-Conserving Therapy vs. Mastectomy with Dr. Medhavi Gupta and Dr. Jessica Young
Surgical Management in Breast Cancer, What to Expect After Surgery with Dr. Medhavi Gupta and Dr. Jessica Young
Surgical Management in Breast Cancer - The Role of Different Types of Surgery and the Management of Patients with Breast Cancer, with Dr. Medhavi Gupta and Dr. Jessica Young
Surgical Management in Breast Cancer - Prophylactic Mastectomy on the Opposite Breast with Dr. Medhavi Gupta and Dr. Jessica Young
Brain Metastases in Breast Cancer
Signs, Symptoms, Screening and Treatment for Brain Metastases in Breast Cancer with Dr. Medhavi Gupta and Dr. Nancy Lin
Surgical Management in Breast Cancer
Surgical Removal of Lymph Nodes - Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection (ALND) with Dr. Medhavi Gupta and Dr. Jessica Young
Vacunas contra el COVID en pacientes con cancer con los Dres. Luis Raez, Estalemari Rodríguez, y Ticiana Leal
COVID Vaccines in Cancer Patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana Leal
Usos de la Telemedicina para el tratamiento de pacientes con cancer con los Dres. Luis Raez, Estalemari Rodríguez, y Ticiana Leal
Uses of Telemedicine for the treatment of cancer patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana Leal
Impacto de la Pandemia del Covid-19 en el cuidado de enfermos de cancer con los Dres. Luis Raez, Estalemari Rodríguez, y Ticiana Leal
Impact of the Covid-19 Pandemic on caring for cancer patients with Drs. Luis Raez, Estalemari Rodríguez, and Ticiana Leal
First Quarter 2021 Panel
COVID-19 Variants and the Challenge for Cancer Care
Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.
First Quarter 2021 Panel
What Patients Should Expect Post COVID-19 Vaccination
Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.
First Quarter 2021 Panel
The Continued Use of Telemedicine in Cancer Treatment
Drs. H. Jack West, Jared Weiss, and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.
First Quarter 2021 Panel
Is the COVID-19 Vaccine Safe For Cancer Patients
GRACE 2021 Panel, Changes and Challenges of Consistent Cancer Care During the Ongoing Pandemic
Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.
GRACE 2021 Panel, Changes and Challenges of Consistent Cancer Care During the Ongoing Pandemic
Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the changes and challenges of consistent cancer care during the COVID -19.
GRACE 2021 Panel, Trends & Implications - The COVID-19 Pandemic Impact on Cancer Care
Drs. H. Jack West, Jared Weiss and Ben Levy, members of the GRACE Board of Directors, discuss the impact the COVID -19 pandemic has had on cancer care.
Dr. Johathan Riess joins GRACE to discuss alternatives to radiation for patients with brain metastases.
Dr. Caroline McCoach joins GRACE to discuss optimal treatment for patients with advanced non small cell lung cancer and a BRAF-V600 mutation.
Dr. Heather Wakelee joins GRACE to discuss treatment options for a metastatic non small cell lung cancer diagnosis.
Drs. H. Jack West, Helena Yu and David Spigel discuss Enhertu and the Potential for Treatment of HER2 Positive NSCLC.
Drs. H. Jack West, Helena Yu and David Spigel discuss The SINDAS Trial - The Addition of SBRT to a Systemic EGFR inhibitor TKI in EGFR positive NSCLC
Drs. H. Jack West, David Spigel and Helena Yu discuss new potenteial treatments for MET and RET Positive NSCLC: Capmatinib/Tabrecta and BLU-667/Pralsetinib
Dr. H. Jack West discusses if EGFR Inhibitor therapy can treat and prevent brain metastases
Dr. Caroline McCoach discusses What are the options after a patient with an ALK-positive advanced NSCLC develops resistance on Alecensa-alectinib
GRACECast - LCVL Dr. Millie Das discusses What is the role of immunotherapy for unresectable Stage 3 NSCLC today
Dr. Howard Jack West discusses ALK Rearrangement-Positive NSCLC and if ALK inhibitors treat and prevent brain metastases?
Dr. Heather Wakelee discusses whether blood-based mutation-testing can help shape treatment decisions for advanced NSCLC.
Dr. Heather Wakelee discusses which patients should receive consolidation immunotherapy after chemo radiation for stage 3 unresectable non small cell lung cancer.
Dr. H. Jack West discusses if local therapies improve outcomes for patients with stage IV NSCLC who have a very good response to first line systemic therapy
Dr. Joel Neal discusses pre-operative immunotherapy and if it could improve outcomes in early stage NSCLC. Why trials are looking at this approach.
Dr. Millie Das discusses the leading treatment options for patients with low or negative tumor PD-L1 expression and advanced nonsquamous NSCLC today.
Dr. Dr. Joel Neal discusses patients with an EGFR mutation positive advanced non small cell lung cancer and if they can benefit from immunotherapy.
Dr. Caroline McCoach discusses ALK Rearrangement-Positive NSCLC and the leading first line treatment options for advanced NSCLC harboring an ALK rearrangement today
Dr. Joel Neal discusses Small Cell Lung Cancer and whether or not immunotherapy can help patients with small cell lung cancer
Dr. Matthew Gubens discusses Targeted therapies in NSCLC PD-L1 Expression and the leading treatment options for patients with low or negative tumor PD-L1 expression and advanced squamous NSCLC today
Dr. Jonathan Reiss discusses EGFR Mutation and the best first line treatment for patients with advanced EGFR mutation-positive NSCLC today
Dr H. Jack West discusses Immunotherapy in NSCLC, and which patients with advanced NSCLC are good candidates for first line immunotherapy alone today?
Dr. Jonathan Reiss discusses the current standard of care for patients with extensive stage small cell lung cancer.
Dr. Millie Das discusses leading treatment options for patients with non small cell lung cancer and hugh tumor PDL1 expression
Dr. Millie Das discusses treatment options for patients with advanced non small cell lung cancer and a HER2-ERBB2 mutation.
Dr. Millie Das discusses whether immunotherapy has activity in malignant pleural mesothelioma.
Dr. Stephen Liu, member of the GRACE faculty, discusses leading treatment options for patients with negative tumor pdl-1 in non small cell lung cancer.
For more information visit www.cancerGRACE.org
Dr. Stephen Liu, member of the GRACE faculty, discusses immunotherapy for small cell lung cancer.
For more information visit www.cancerGRACE.org
Dr. Josh Bauml, member of the GRACE faculty, discusses emerging molecular targets in non small cell lung cancer for RET fusions.
For more information visit www.cancerGRACE.org
Dr. Josh Bauml, member of the GRACE faculty, discusses emerging molecular targets in non small cell lung cancer with a MET mutation.
for more information visit www.cancerGRACE.org
Dr. Jared Weiss, GRACE VP on the Board of Directors and Faculty for GRACE discusses updates for the treatment of Small Cell Lung Cancer.
For more info, visit www.cancerGRACE.org
Dr. Jared Weiss, Vice President of the GRACE Board of Directors and GRACE faculty, discusses the new TKIs for Stage IV Non Small Cell Lung Cancer mutations including MET, RET, and HER2.
Dr. Jared Weiss, Vice President of the GRACE Board of Directors and GRACE faculty, discusses the ADAURA trial; the first global trial for an EGFR inhibitor to show statistically significant and clinically meaningful benefit in adjuvant treatment of lung cancer.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.
Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.
In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds patient progression in a case with EGFR mutation, and what are the next steps.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.
Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.
In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds a case with an EGFR Mutation and High PDL1. The discussion centers around the role of immunotherapy in treatment decisions.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.
Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.
In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation with MET amplification. They review treatment decisions and the importance of the level of MET amplification.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
In part three of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19.
GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy discuss cancer and Covid-19 and how the ongoing pandemic is effecting in person patient care.
Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
Part 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
Part 3 - Challenges and the Future Outlook for In Person Patient Care
To join the conversation, visit https://cancergrace.org/forum.
In part two of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19.
GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19 and how the ongoing pandemic is effecting patient care. In this series update, we discuss an update on the use of telemedicine in patient care during the pandemic.
Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
Part 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
Part 3 - Challenges and the Future Outlook for In Person Patient Care
To join the conversation, visit https://cancergrace.org/forum.
In part one of this three part video series update, presented in July of 2020, GRACE Faculty and Members of the Board of Directors continue their candid discussions regarding cancer and Covid-19.
GRACE Board Members Drs. H. Jack West, Jared Weiss and Ben Levy have another candid discussion regarding cancer and Covid-19 and how the ongoing pandemic is effecting patient care. In this series update, we discuss changes to management in patient care, the use of telemedicine and future challenges, as well as other issues relating to a cancer diagnosis in the middle of a pandemic.
Part 1 - How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
Part 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
Part 3 - Challenges and the Future Outlook for In Person Patient Care
To join the conversation, visit https://cancergrace.org/forum.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.
Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.
In this series, the doctors discuss a series of cases related to EGFR Mutations. In this discussion they review the recommended treatment for a common EGFR mutation.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.
Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.
In this series, the doctors discuss a series of cases related to EGFR Mutations. In this case, the discussion surrounds an EGFR mutation treated with Tagrisso, and progression while on treatment.
The doctors also discuss the role of repeat biopsy.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic.
In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike.
Does this new process create new helpful tools?
How does the informality of online visits affect the Doctor/Patient relationship?
Are there limitations to telemedicine - when and who is it good for, does it disrupt the ritualization of doctor/patient visits, and the ability to assess the patient?
Is it sustainable?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic.
In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike.
Does this new process create new helpful tools?
How does the informality of online visits affect the Doctor/Patient relationship?
Are there limitations to telemedicine - when and who is it good for, does it disrupt the ritualization of doctor/patient visits, and the ability to assess the patient?
Is it sustainable?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
In April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy had a candid discussion regarding telemedicine in the time of the current pandemic.
In this time of social distancing and limiting clinic exposure, the sudden need for telemedicine and web consults is perhaps changing the future of medicine on a faster pace than we have previously thought possible. In this three part series the doctors discuss a wide range of topics surrounding the use of telemedicine and potential challenges for providers and patients alike.
Does this new process create new helpful tools?
How does the informality of online visits affect the Doctor/Patient relationship?
Are there limitations to telemedicine - when and who is it good for, does it disrupt the ritualization of doctor/patient visits, and the ability to assess the patient?
Is it sustainable?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.
Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.
In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.
Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.
In this series, the doctors discuss a series of cases related to EGFR Mutations - is there a place for chemotherapy and an EGFR inhibitor concurrently or sequentially in treatment decisions?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.
Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.
Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.
The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive asymptomatic brain metastases. Is the standard approach of focal radiation before beginning ALK inhibitor appropriate, or do you begin with the ALK Inhibitor?
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.
Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.
Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.
The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is surrounding what the approach for first line treatment would be for a patient with good performance status, lung adenocarcinoma, metastatic disease and adrenal lesions.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.
Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.
Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.
The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive asymptomatic brain metastases. Is the standard approach of focal radiation before beginning ALK inhibitor appropriate, or do you begin with the ALK Inhibitor?
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.
Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.
The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss progression after success on Alk inhibitors, and if there is a role for combination therapies like chemo/Avastin and immunotherapy.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.
Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.
Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.
The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, they discuss developing resistance to Alk inhibitors, treatment approaches and biopsies, and what are the next steps.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.
Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.
The doctors discuss a series of cases related to a diagnosis of NSCLC. In this video, the discussion is regarding a patient with a HER2 mutation, what is the clinical significance, and how does a positive HER2 mutation effect treatment decisions?
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.
Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center.
Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.
The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is surrounding what the approach for first line treatment would be for a patient with good performance status, lung adenocarcinoma, metastatic disease and adrenal lesions.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.
Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.
In this series, the doctors discuss a series of cases related to an EGFR mutation. In this podcast, the discussion is regarding uncommon EXON 20 mutation, suggested treatments, targeted therapy and clinical trials.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
In this podcast series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19.
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.
In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.
Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
In this podcast series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19.
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.
In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.
Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
In this podcast series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19.
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.
In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.
Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
In this video series, presented in April of 2020, GRACE Board Members Dr. H. Jack West, Dr. Jared Weiss and Dr. Ben Levy have a candid discussion regarding cancer and Covid 19.
In this time of social distancing and limiting clinic exposure, the doctors sat down in their respective homes to discuss some of the questions we all hear regarding these unprecedented times, and how they effect primarily cancer patients.
In this four part series, we discuss testing, ongoing cancer treatment, and many other issues relating to a cancer diagnosis in the middle of a pandemic.
Part 1 - Should cancer patients get tested even if they show no symptoms?
Part 2 - Do cancer patients have a higher risk for Covid 19?
Part 3 - What preventive measures are trustworthy?
Part 4 - Is the standard of care changing for cancer patients because of the pandemic?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach.
Dr. Wakelee is Professor of Medicine in the Division of Medicine and Oncology at Stanford University Medical Center.
Dr. McCoach is Assistant Professor in the Thoracic Medical Oncology Division of the UCSF Helen Diller Comprehensive Cancer Center in San Francisco, California.
In this series, the doctors discuss a series of cases related to EGFR Mutations. For EGFR mutations and the FLAURA trial, is there a difference in data based on demographics and how can that effect treatment decisions?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC .
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.
Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.
Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss Checkmate 227's suggestion of an immunotherapy combination of Yervoy (Ipilimumab) and Opdivo (Nivolumab) as another treatment option.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC .
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.
Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.
Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss Tumor Mutational Burden (TMB) and it's value in testing.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC .
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.
Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.
Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the standard treatment of chemotherapy and radiation followed by immunotherapy and the risk of pneumonitis.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC .
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.
Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.
Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the standard treatment of chemotherapy and radiation followed by immunotherapy and the best schedule for Durvalumab (Imfinzi) in a variety of patient scenarios.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC .
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.
Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.
Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the standard treatment of chemotherapy and radiation followed by immunotherapy and the approach for a patient with PDL1 score of 0. Would immunotherapy be beneficial?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC .
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.
Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.
Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss a patient with unresectable NSCLC, and whether the timing of treatment makes a difference in their response.
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC .
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.
Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.
Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss a stage 3 frail patient with unresectable NSCLC, Unresectable NSCLC with competing risks, and if the standard treatment is the best approach.
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding unresectable NSCLC .
Dr. Millie Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis.
Dr. Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. He is an Assistant Clinical Professor of Medicine at UCSF.
Recently the doctors sat down to discuss a series of case-based scenarios. In this video, the doctors discuss the option of molecular testing for stage 3 NSCLC, and whether or not the outcome effects treatment decisions.